These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 27645621)

  • 1. Patterns of recurrence and survival in neuroendocrine cervical cancer.
    Stecklein SR; Jhingran A; Burzawa J; Ramalingam P; Klopp AH; Eifel PJ; Frumovitz M
    Gynecol Oncol; 2016 Dec; 143(3):552-557. PubMed ID: 27645621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine carcinoma of the cervix: a systematic review of the literature.
    Tempfer CB; Tischoff I; Dogan A; Hilal Z; Schultheis B; Kern P; Rezniczek GA
    BMC Cancer; 2018 May; 18(1):530. PubMed ID: 29728073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinicopathological features and treatment modalities associated with survival of neuroendocrine cervical carcinoma in a Chinese population.
    Zhang X; Lv Z; Lou H
    BMC Cancer; 2019 Jan; 19(1):22. PubMed ID: 30616631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multimodality therapy in early-stage neuroendocrine carcinoma of the uterine cervix.
    Boruta DM; Schorge JO; Duska LA; Crum CP; Castrillon DH; Sheets EE
    Gynecol Oncol; 2001 Apr; 81(1):82-7. PubMed ID: 11277655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring a Better Adjuvant Treatment for Surgically Treated High-Grade Neuroendocrine Carcinoma of the Cervix.
    Wang R; Xiao Y; Ma L; Wu Z; Xia H
    Gynecol Obstet Invest; 2022; 87(6):398-405. PubMed ID: 36273460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Factors and Impact of Minimally Invasive Surgery in Early-stage Neuroendocrine Carcinoma of the Cervix.
    Kim JH; Shim SH; Nam SH; Lee SW; Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT
    J Minim Invasive Gynecol; 2020; 27(7):1558-1565. PubMed ID: 32084588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural history and outcome of neuroendocrine carcinoma of the cervix.
    Margolis B; Tergas AI; Chen L; Hou JY; Burke WM; Hu JC; Ananth CV; Neugut AI; Hershman DL; Wright JD
    Gynecol Oncol; 2016 May; 141(2):247-254. PubMed ID: 26873865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence.
    Viswanathan AN; Deavers MT; Jhingran A; Ramirez PT; Levenback C; Eifel PJ
    Gynecol Oncol; 2004 Apr; 93(1):27-33. PubMed ID: 15047210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the initial site of metastases on post-recurrence survival for neuroendocrine cervical cancer.
    Pan B; Wan T; Jiang Y; Zheng X; Liu P; Xiang H; Zheng M
    BMC Cancer; 2022 Jun; 22(1):655. PubMed ID: 35698184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small cell neuroendocrine carcinoma of the cervix: analysis of the prognosis and role of radiation therapy for 43 cases.
    Lan-Fang L; Hai-Yan S; Zuo-Ming Y; Jian-Qing Z; Ya-Qing C
    Eur J Gynaecol Oncol; 2012; 33(1):68-73. PubMed ID: 22439409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distant organ metastasis patterns and prognosis of neuroendocrine cervical carcinoma: a population-based retrospective study.
    Li Q; Yu J; Yi H; Lan Q
    Front Endocrinol (Lausanne); 2022; 13():924414. PubMed ID: 36051393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical treatment for neuroendocrine carcinoma of the uterine cervix.
    Kasamatsu T; Sasajima Y; Onda T; Sawada M; Kato T; Tanikawa M
    Int J Gynaecol Obstet; 2007 Dec; 99(3):225-8. PubMed ID: 17897648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-L1 expression and prognosis in definitive radiotherapy patients with neuroendocrine cervical carcinoma.
    Li H; Li X; Yang M; Su H; Zhang J; Hu C; Sun Y; Hu D; Chen L
    J Clin Transl Res; 2023 Aug; 9(4):272-281. PubMed ID: 37593242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Features of Neuroendocrine Carcinoma of the Uterine Cervix: A Single-Institution Retrospective Review.
    Nagao S; Miwa M; Maeda N; Kogiku A; Yamamoto K; Morimoto A; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Sakuma T; Fujiwara K
    Int J Gynecol Cancer; 2015 Sep; 25(7):1300-5. PubMed ID: 26166556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic characteristics, oncologic outcomes, and prognostic factors in neuroendocrine cervical carcinoma: a Neuroendocrine Cervical Tumor Registry study.
    Salvo G; Flores Legarreta A; Ramalingam P; Jhingran A; Bhosale P; Saab R; Gonzales NR; Chisholm GB; Frumovitz M
    Int J Gynecol Cancer; 2023 Sep; 33(9):1359-1369. PubMed ID: 37567596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive Immune-Cell Therapy for the Treatment of Neuroendocrine Carcinoma of the Uterine Cervix.
    Goto S; Terao Y; Kamigaki T; Takimoto R; Naitoh K; Makita K; Yasumoto K; Okada S; Takizawa K; Yokomichi N; Suzuki N; Takeda S
    Anticancer Res; 2020 Aug; 40(8):4741-4748. PubMed ID: 32727800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unfavorable prognosis of small cell neuroendocrine carcinoma of the uterine cervix: a retrospective matched case-control study.
    Lee SW; Nam JH; Kim DY; Kim JH; Kim KR; Kim YM; Kim YT
    Int J Gynecol Cancer; 2010 Apr; 20(3):411-6. PubMed ID: 20375806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
    Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
    J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant Platinum-based Chemotherapy Followed by Radical Hysterectomy for Stage Ib2-IIb Adenocarcinoma of the Uterine Cervix - An Italian Multicenter Retrospective Study.
    Gadducci A; Landoni F; Cosio S; Zizioli V; Zola P; Ferrero AM; Lapresa MT; Maggino T; Sartori E
    Anticancer Res; 2018 Jun; 38(6):3627-3634. PubMed ID: 29848719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brachytherapy should not be omitted when treating locally advanced neuroendocrine cervical cancer with definitive chemoradiation therapy.
    Robin TP; Amini A; Schefter TE; Behbakht K; Fisher CM
    Brachytherapy; 2016; 15(6):845-850. PubMed ID: 27720204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.